Get the Stockscreener App
10.81
0.18%
-0.02
After Hours:
10.82
0.010
+0.09%
4 D Molecular Therapeutics Inc stock is traded at $10.81, with a volume of 705.89K.
It is down -0.18% in the last 24 hours and down -27.98% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$10.83
Open:
$10.83
24h Volume:
705.89K
Relative Volume:
0.74
Market Cap:
$555.04M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-3.2957
EPS:
-3.28
Net Cash Flow:
$-78.56M
1W Performance:
-6.89%
1M Performance:
-27.98%
6M Performance:
-66.07%
1Y Performance:
-15.08%
1-Day Range:
$10.56
$11.12
1-Week Range:
$10.56
$11.77
52-Week Range:
$9.44
$36.25
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
Investor’s Toolkit: Key Ratios for Assessing 4D Molecular Therapeutics Inc (FDMT)’s Performance - The Dwinnex
Profund Advisors LLC Decreases Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics Inc [FDMT] Investment Appeal on the Rise - Knox Daily
4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Top investors say 4D Molecular Therapeutics Inc (FDMT) ticks everything they need - SETE News
4D Molecular Therapeutics, Inc. Expected to Post FY2024 Earnings of ($2.68) Per Share (NASDAQ:FDMT) - MarketBeat
Did 4D Molecular Therapeutics Inc (FDMT) perform well in the last session? - US Post News
Closing Figures: 4D Molecular Therapeutics Inc (FDMT)’s Negative Finish at 11.61, Down -2.44 - The Dwinnex
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
4D Molecular Therapeutics downgraded at Cantor following wet AMD asset data - Seeking Alpha
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down to $11.90 - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down to $11.90 - Defense World
Cantor Fitzgerald Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) to Neutral - MarketBeat
Cantor Fitzgerald Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) to Neutral - Defense World
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference - Yahoo Finance
4D Molecular Therapeutics downgraded at Cantor following wet AMD asset data - MSN
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 14.4% - Defense World
Rhumbline Advisers Has $1.53 Million Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Ratios Uncovered: Breaking Down 4D Molecular Therapeutics Inc (FDMT)’s Trailing Twelve Months Metrics - The Dwinnex
4D Molecular Therapeutics Inc [FDMT] Records 200-Day SMA of $22.26 - Knox Daily
A new trading data show 4D Molecular Therapeutics Inc (FDMT) is showing positive returns. - SETE News
4D Molecular Therapeutics Inc [FDMT] Revenue clocked in at $21.99 million, down -33.37% YTD: What’s Next? - The DBT News
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Increased to $39.00 by Analysts at Chardan Capital - Defense World
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate - AOL
4D Molecular data ‘bode well’ for eye gene therapy, but shares fall - BioPharma Dive
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate - Yahoo Finance
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 14.4% - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) PT Raised to $39.00 - MarketBeat
Chardan maintains stock target, buy rating on 4D Molecular Therapeutics - Investing.com
BMO Capital sticks with $40 target for 4D Molecular stock as 4D-150 PhIII prospects remain strong - Investing.com
4D Molecular reports promising wet AMD trial results By Investing.com - Investing.com Australia
4D Molecular data ‘bode well’ for eye gene therapy, but shares fall - Yahoo Finance
4D Molecular Therapeutics’ (FDMT) Outperform Rating Reaffirmed at Leerink Partners - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given "Outperform" Rating at Leerink Partners - MarketBeat
Goldman Sachs reiterates Buy on 4D Molecular Therapeutics, highlights promising gene therapy results - Investing.com
4DMT’S Gene Therapy for AMD Clears Phase II, Heads to Late-Stage Studies - BioSpace
FDMT Stock: Exploring 4D Molecular Therapeutics Inc’s Growth - The InvestChronicle
Objective long/short (FDMT) Report - Stock Traders Daily
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 4.2% - MarketBeat
4D Molecular reports promising wet AMD trial results By Investing.com - Investing.com Canada
4d Molecular Therapeutics executive sells $8.2k in stock By Investing.com - Investing.com Australia
4D Molecular reports promising wet AMD trial results - Investing.com India
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day - ForexTV.com
4D Molecular reports promising wet AMD trial results - Investing.com
4d Molecular Therapeutics executive sells $8.2k in stock By Investing.com - Investing.com South Africa
4D Molecular reports promising wet AMD trial results By Investing.com - Investing.com UK
4d Molecular Therapeutics executive sells $8.2k in stock - Investing.com India
4d Molecular Therapeutics executive sells $8.2k in stock By Investing.com - Investing.com Canada
4d Molecular Therapeutics executive sells $8.2k in stock - Investing.com
4d Molecular Therapeutics executive sells $8.2k in stock By Investing.com - Investing.com UK
4D Molecular announces data from PRISM, 4FRONT trials - TipRanks
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):